Combined Therapy of Low-Dose Angiotensin Receptor-Neprilysin Inhibitor and Sodium-Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects

• Principais autores: Donghyun Kim (Autor), Gyuho Jang (Autor), Jaetaek Hwang (Autor), Xiaofan Wei (Autor), Hyunsoo Kim (Autor), Jinbae Son (Autor), Sang-Jae Rhee (Autor), Kyeong-Ho Yun (Autor), Seok-Kyu Oh (Autor), Chang-Myung Oh (Autor), Raekil Park (Autor)
• Formato: Livro
• Publicado em: MDPI AG, 2022-11-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Although cancer-therapy-related cardiac dysfunction (CTRCD) is a critical issue in clinical practice, there is a glaring lack of evidence regarding cardiotoxicity management. To determine an effective and suitable dosage of treatment using angiotensin receptor-neprilysin inhibitors (ARNI) with sodiu...